What Karyopharm Therapeutics does

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company founded in 2008 and headquartered in Newton, Massachusetts (with a European subsidiary in Munich, Germany), publicly listed on NASDAQ under ticker KPTI. The company has pioneered the development of oral Selective Inhibitor of Nuclear Export (SINE) technology targeting the nuclear export protein XPO1, a mechanism designed to accumulate tumor suppressor proteins in the cell nucleus and induce apoptosis in cancer cells. Its lead asset is XPOVIO (selinexor), a first-in-class oral XPO1 inhibitor approved by the FDA for relapsed/refractory multiple myeloma (initial 2019 approval, expanded 2020 combination indication), by the European Commission (March 2021) and UK MHRA (May 2021) under the brand NEXPOVIO, and approved in over 50 ex-U.S. countries.

The company's product portfolio consists of one commercial product (XPOVIO/NEXPOVIO) and a clinical pipeline spanning hematologic malignancies and solid tumors. Pipeline assets include eltanexor (KPT-8602), a second-generation SINE compound with improved therapeutic window; KPT-9274, a first-in-class dual PAK4/NAMPT inhibitor for advanced solid malignancies; and verdinexor (KPT-335), under investigation for viral and inflammatory indications plus veterinary use via Anivive. In March 2026, the Phase 3 SENTRY trial of selinexor plus ruxolitinib in JAK inhibitor-naïve myelofibrosis met its co-primary SVR35 endpoint (49.8% vs 28%, OR 2.58, p<0.0001) with a >50% reduction in risk of death (HR 0.43), supporting a potential new indication filing. Additional trials include XPORT-EC-042 in TP53 wild-type endometrial cancer.

Karyopharm operates a hybrid go-to-market model: direct commercial sales infrastructure in the United States for XPOVIO, complemented by ex-U.S. licensing and distribution partnerships with Menarini Group/Stemline (EU and global ex-U.S.), Antengene (Asia-Pacific including China, Taiwan, Hong Kong, Australia, South Korea, Singapore), Neopharm (Israel), and FORUS (other territories). FY2025 total revenue was $146.1 million with Q1 2026 revenue of $35.1 million (17% YoY growth) and FY2026 guidance of $130-150 million. The company employs between 251-500 people, is recognized as a top workplace (USA Today 2025, Boston Business Journal), and has been engaged with Centerview Partners to explore strategic and financing alternatives amid three consecutive private placements totaling approximately $295M since late 2022.

Name

Karyopharm Therapeutics

Legal name

Karyopharm Therapeutics Inc.

Website

https://karyopharm.com

Company type

Public

Founded year

2008

Operating status

Operating

Headcount range

251–500 employees

Short description

Karyopharm Therapeutics is a commercial-stage pharmaceutical company that develops oral SINE/XPO1 inhibitors for cancer. It markets XPOVIO (selinexor) for multiple myeloma in the U.S. and through licensing partners across 50+ countries, with a pipeline targeting myelofibrosis and solid tumors.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (54169)

SIC

Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)

akta.pro secondary industries

Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH), Thoracic (Lung) Oncology (HLAKAFAL)

Keywords

• Oncology drug development
• Nuclear export inhibitors
• Multiple myeloma treatment
• Cancer therapeutics
• Specialty pharmaceuticals

Headquarters

HQ city

Newton

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

1. XPOVIO Product Sales (U.S.): Direct commercial sales of XPOVIO (selinexor) in the United States for approved multiple myeloma indications. Q1 2026 U.S. net product revenue of $29.2 million, representing 17% year-over-year growth.
2. Partner Licensing (Ex-U.S.): Licensing and distribution partnerships with Antengene, Menarini, Neopharm, and FORUS for commercialization of XPOVIO/NEXPOVIO in ex-U.S. territories including EU, UK, Mainland China, Taiwan, Hong Kong, Australia, South Korea, Singapore, Israel, and Canada.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Karyopharm Therapeutics is a commercial-stage pharmaceutical company that develops and markets XPOVIO (selinexor), a first-in-class oral selective inhibitor of nuclear export (SINE) that targets the XPO1 nuclear export protein. XPOVIO is FDA-approved for relapsed/refractory multiple myeloma in the U.S. and marketed as NEXPOVIO in over 50 ex-U.S. countries. The company is advancing its SINE technology pipeline across hematologic malignancies (myelofibrosis, myelodysplastic syndromes, AML) and solid tumors (endometrial cancer, liposarcoma, glioma).

Product overview

Karyopharm Therapeutics is a commercial-stage pharmaceutical company with one marketed product and multiple investigational candidates in its pipeline. The core product is XPOVIO (selinexor), an oral XPO1 inhibitor approved for multiple myeloma in the U.S. and internationally as NEXPOVIO. The company is advancing selinexor in additional indications including myelofibrosis and TP53 wild-type endometrial cancer. The pipeline includes second-generation SINE compound eltanexor, dual PAK4/NAMPT inhibitor KPT-9274, and antiviral candidate verdinexor. The company leverages its SINE technology platform to develop therapies targeting nuclear export inhibition across hematologic malignancies and solid tumors.

Differentiator

Problem solved

Functional benefit

Brands

• XPOVIO®: First-in-class oral XPO1 inhibitor (selinexor) approved for multiple myeloma in the U.S.
• NEXPOVIO®

Products and services

• XPOVIO / NEXPOVIO (selinexor) First-in-class oral selective inhibitor of nuclear export (SINE) targeting the XPO1 protein, approved for treatment of adult patients with relapsed or refractory multiple myeloma. Marketed as XPOVIO in the United States and NEXPOVIO in ex-U.S. markets including EU, UK, Mainland China, Taiwan, Hong Kong, Australia, South Korea, Singapore, Israel, and Canada. Used in combination with dexamethasone (Xd) or with bortezomib and dexamethasone (XVd) for multiple myeloma patients.

Quantifiable outcome

• 49.8% SVR35 at week 24 in myelofibrosis vs 28% for ruxolitinib alone (OR 2.58, p<0.0001)
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered minor, flagship and core.

• Anivive LifesciencesminorOEM/ Whitelabel/ Licensing Partner · 1 May 2017Exclusive worldwide licensing agreement for verdinexor (KPT-335) for the treatment of cancer in companion animals. Anivive responsible for research, development, and commercialization for veterinary use.
• Menarini GroupflagshipStrategic or Co-development PartnerGlobal licensing partnership for selinexor outside the U.S. Menarini holds global rights (except U.S.) and commercializes under NEXPOVIO brand. Collaboration on Phase 3 SENTRY trial for myelofibrosis with subsidiary Stemline Therapeutics.
• Stemline Therapeutics (Menarini subsidiary)flagshipStrategic or Co-development PartnerCollaborated on Phase 3 SENTRY trial for selinexor plus ruxolitinib in myelofibrosis. Presented results at EHA 2026 Congress. Holds global rights for selinexor outside U.S.
• AntengenecoreChannel Partner/ Reseller/ DistributorPartner for commercialization of XPOVIO/NEXPOVIO in Asia-Pacific region including China, Taiwan, Hong Kong, South Korea, Singapore, and Australia.
• NeopharmcoreChannel Partner/ Reseller/ DistributorPartner for commercialization of XPOVIO in Israel.
• FORUScoreChannel Partner/ Reseller/ DistributorPartner for commercialization of XPOVIO in specified ex-U.S. territories.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Bristol-Myers Squibb: Acquired Celgene and inherited the multiple myeloma franchise (Revlimid, Pomalyst, Abecma CAR-T) and also markets Inrebic (fedratinib) for myelofibrosis. Directly competes with Karyopharm in both lead indication (multiple myeloma) and expansion indication (myelofibrosis).
• Johnson & Johnson: Markets Darzalex (daratumumab), the multiple myeloma market leader, plus Carvykti (cilta-cel CAR-T therapy) through Janssen. Direct competitor in relapsed/refractory multiple myeloma with substantially greater resources and market position.
• Amgen: Markets Kyprolis (carfilzomib), a second-generation proteasome inhibitor approved for multiple myeloma, and has broader oncology franchise including Blincyto and Lumakras. Directly competes with XPOVIO in multiple myeloma combination regimens.
• Takeda Pharmaceutical: Historically led multiple myeloma market with Velcade (bortezomib, now generic) and continues with Ninlaro (ixazomib) oral proteasome inhibitor. Direct comparator for selinexor combination regimens including the XVd triplet used by Karyopharm.
• Sanofi: Markets Sarclisa (isatuximab), a CD38-directed monoclonal antibody approved for multiple myeloma that directly competes with J&J's Darzalex. Represents a growing competitive threat in the relapsed/refractory multiple myeloma space where XPOVIO is positioned.
• GSK: Owns Blenrep (belantamab mafodotin) for multiple myeloma (relaunched) and Ojjaara (momelotinib) for myelofibrosis acquired through Sierra Oncology. Competes with Karyopharm in both multiple myeloma and myelofibrosis indications.
• Sobi (Swedish Orphan Biovitrum): Acquired CTI BioPharma and markets Vonjo (pacritinib), an oral JAK2/IRAK1 inhibitor approved for myelofibrosis patients with severe thrombocytopenia. Direct competitor to selinexor's planned myelofibrosis indication, particularly in cytopenic patients.
• Geron Corporation: Markets Rytelo (imetelstat), a telomerase inhibitor approved in 2024 for transfusion-dependent anemia in lower-risk MDS. Hematology-focused small-cap biotech with similar commercial-stage profile and competes for similar oncology specialty prescribers and capital.

Broad incumbents

• AbbVie: Broad oncology franchise including Imbruvica (BTK inhibitor) and Venclexta (BCL-2 inhibitor), with significant hematology sales force. Larger incumbent in oncology/hematology with overlapping prescriber base for XPOVIO and resources to develop competing mechanisms.
• Pfizer: Large pharmaceutical incumbent with broad oncology portfolio and historical presence in hematology. Major competitor for institutional capital and partnership opportunities, with global commercial infrastructure that could pursue similar nuclear export or hematology targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Karyopharm
• LinkedInlinkedin.com/company/karyopharm-therapeutics-inc
• Facebookfacebook.com/KaryopharmTherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries1 record

Funding overview

Funding rounds11 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Karyopharm Therapeutics